UY31660A1 - Sistemas de administración de drogas que contienen estradiol - Google Patents

Sistemas de administración de drogas que contienen estradiol

Info

Publication number
UY31660A1
UY31660A1 UY031660A UY31660A UY31660A1 UY 31660 A1 UY31660 A1 UY 31660A1 UY 031660 A UY031660 A UY 031660A UY 31660 A UY31660 A UY 31660A UY 31660 A1 UY31660 A1 UY 31660A1
Authority
UY
Uruguay
Prior art keywords
drug administration
containing estradiol
systems containing
administration systems
wafers
Prior art date
Application number
UY031660A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Holler
Sofia Alincickunz
Lldiko Terebesi
Sascha General
Diefenbach Konstanze
Matthias Schafer
Christian Zurth
Adrian Funke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39365963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31660(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31660A1 publication Critical patent/UY31660A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
UY031660A 2008-02-13 2009-02-13 Sistemas de administración de drogas que contienen estradiol UY31660A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08002633 2008-02-13

Publications (1)

Publication Number Publication Date
UY31660A1 true UY31660A1 (es) 2009-09-30

Family

ID=39365963

Family Applications (1)

Application Number Title Priority Date Filing Date
UY031660A UY31660A1 (es) 2008-02-13 2009-02-13 Sistemas de administración de drogas que contienen estradiol

Country Status (27)

Country Link
US (1) US20110097405A1 (enExample)
EP (1) EP2249803A2 (enExample)
JP (1) JP2011511823A (enExample)
KR (1) KR20100125309A (enExample)
CN (1) CN101945646A (enExample)
AR (1) AR070375A1 (enExample)
AU (1) AU2009214193A1 (enExample)
BR (1) BRPI0908477A2 (enExample)
CA (1) CA2714340A1 (enExample)
CL (1) CL2009000326A1 (enExample)
CO (1) CO6290633A2 (enExample)
CR (1) CR11632A (enExample)
DO (1) DOP2010000252A (enExample)
EA (1) EA201001245A1 (enExample)
EC (1) ECSP10010400A (enExample)
IL (1) IL206640A0 (enExample)
MA (1) MA32073B1 (enExample)
MX (1) MX2010008940A (enExample)
NZ (1) NZ586666A (enExample)
PA (1) PA8816001A1 (enExample)
PE (1) PE20091471A1 (enExample)
TN (1) TN2010000302A1 (enExample)
TW (1) TW200940095A (enExample)
UA (1) UA102680C2 (enExample)
UY (1) UY31660A1 (enExample)
WO (1) WO2009101021A2 (enExample)
ZA (1) ZA201006517B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
GB201200062D0 (en) 2012-01-04 2012-02-15 Innotesto Bvba Estradiol oromucosal liquid compositions
AU2012385956B2 (en) 2012-07-23 2017-03-30 Crayola, Llc Dissolvable films and methods of using the same
HK1247283A1 (zh) * 2015-03-02 2018-09-21 科罗纳里康赛普茨有限责任公司 用於peg代谢物及peg分解产物检测的化合物及方法
CN119055659A (zh) * 2024-09-03 2024-12-03 南通大学 17α雌二醇或其化学修饰衍生物在制备预防和/或治疗男性性腺功能低下的药物中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136162A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
JPS56140915A (en) * 1980-04-07 1981-11-04 Yamanouchi Pharmaceut Co Ltd Pharmaceutical preparation for solid drug
DE3347125A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
ATE155681T1 (de) * 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
DE4426709A1 (de) * 1994-07-20 1996-01-25 Schering Ag Steroidale Sexualhormone enthaltende feste Arzneiformen
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
CA2329005C (en) * 1998-04-17 2006-01-03 Ortho-Mcneil Pharmaceutical, Inc. Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
CH693905A5 (de) * 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20030092658A1 (en) * 2001-02-02 2003-05-15 Meyers Rachel E. Novel human enzyme family members and uses thereof
WO2001077139A1 (de) * 2000-04-12 2001-10-18 Schering Aktiengesellschaft 8.beta.-hydrocarbyl-substituierte estratriene als selektiv wirksame estrogene
EP1216712A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
EP1390038A2 (en) * 2001-05-16 2004-02-25 Endeavor Pharmaceuticals Treatment of conditions relating to hormone deficiencies by administration of progestins
CN1473035B (zh) * 2001-07-27 2012-07-18 安斯泰来制药有限公司 含有口腔内迅速崩解片剂用缓释微粒的组合物及其制造方法
DE10207394B4 (de) * 2002-02-21 2007-03-29 Lts Lohmann Therapie-Systeme Ag Geschmacksmaskierte oblatenförmige Arzneizubereitung
JP5037779B2 (ja) * 2002-02-21 2012-10-03 バイエル ファーマ アクチエンゲゼルシャフト １又は複数のステロイド、１又は複数のテトラヒドロ葉酸成分およびビタミンｂ１２を含む医薬組成物
US20070059346A1 (en) * 2003-07-01 2007-03-15 Todd Maibach Film comprising therapeutic agents
KR20060126688A (ko) * 2003-12-09 2006-12-08 다이닛본 스미토모 세이야꾸 가부시끼가이샤 약물-함유 입자 및 그 입자를 함유하는 고형 제제
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
US20050220825A1 (en) * 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
DE102004023984A1 (de) * 2004-05-14 2005-12-08 Hf Arzneimittelforschung Gmbh Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
DE102005015128B4 (de) * 2005-03-31 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Wafer enthaltend Steroidhormone
US20060275364A1 (en) * 2005-05-26 2006-12-07 Ahmed Salah U Flexible Solid Dosage Forms and Methods of Making and Using the Same
DE102005058569B4 (de) * 2005-12-08 2010-07-15 Lts Lohmann Therapie-Systeme Ag Schaumwafer mit Polyvinylalkohol-Polyethylenglycol-Pfropfcopolymer
DE102005062270A1 (de) * 2005-12-24 2007-06-28 Bayer Technology Services Gmbh Geschmacksmaskierung von Pulvern
DE102006003512A1 (de) * 2006-01-24 2007-08-02 Bayer Schering Pharma Ag Plättchenförmige Arzneimittel zur transbukkalen Applikation von Arzneistoffen
EP1867321A3 (en) * 2006-06-07 2008-11-19 Familplan Consulting Ltd. A pharmaceutical product adapted for oral transmucosal administration comprising a pharmaceutical agent
DE102006027796A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Estrogen-Gestagen-Kombinationen
DE102006027792A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antidepressiva-Kombinations-Wafer
US20080058272A1 (en) * 2006-08-29 2008-03-06 Juergen Becker Nonamer Peptides for Cancer Treatment

Also Published As

Publication number Publication date
CN101945646A (zh) 2011-01-12
TN2010000302A1 (en) 2011-11-11
JP2011511823A (ja) 2011-04-14
EP2249803A2 (en) 2010-11-17
ECSP10010400A (es) 2010-09-30
CO6290633A2 (es) 2011-06-20
CR11632A (es) 2010-10-05
CA2714340A1 (en) 2009-08-20
MX2010008940A (es) 2010-10-05
DOP2010000252A (es) 2010-08-31
TW200940095A (en) 2009-10-01
US20110097405A1 (en) 2011-04-28
WO2009101021A3 (en) 2009-12-30
ZA201006517B (en) 2014-02-26
NZ586666A (en) 2012-04-27
AR070375A1 (es) 2010-03-31
PE20091471A1 (es) 2009-10-25
IL206640A0 (en) 2010-12-30
BRPI0908477A2 (pt) 2018-03-27
CL2009000326A1 (es) 2010-07-19
MA32073B1 (fr) 2011-02-01
PA8816001A1 (es) 2009-09-17
KR20100125309A (ko) 2010-11-30
EA201001245A1 (ru) 2011-04-29
WO2009101021A2 (en) 2009-08-20
AU2009214193A1 (en) 2009-08-20
UA102680C2 (ru) 2013-08-12

Similar Documents

Publication Publication Date Title
ES2649340T3 (es) Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
AR127861A2 (es) Composición farmacéutica que comprende inhibidores del proteasoma peptídico y ciclodextrina
BR112016012615A8 (pt) sistemas, e kit
AR059174A1 (es) Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas)
CR20110072A (es) Sistema de administración de drogas que contiene progestina
BR112016000194A8 (pt) forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
CR20120493A (es) Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis
CR20110110A (es) Composicion farmaceutica
EP3494959A3 (en) Sustained release latanoprost implant
IL299897B2 (en) Devices and methods for administering multiple units of drug
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
PE20091574A1 (es) Sistema de administracion de drogas con efecto estabilizante
BR112014031914A2 (pt) cápsula de estradiol solúvel para inserção vaginal
BR112014002141A2 (pt) crizotinib para uso no tratamento de câncer
PH12013502325A1 (en) Drug delivery system
DOP2010000252A (es) Sistemas de administracion de drogas que contienen estradiol
UY32822A (es) Composiciones farmacéuticas para el tratamiento de cáncer y otras enfermedades o trastornos
MX2018008196A (es) Tratamiento para cancer de mama usando una combinacion de una formulacion liposomal cationica de taxano, una formulacion no liposomal de taxano y un agente activo adicional.
CO6771460A2 (es) Tratamiento de la atrofia vaginal con nueva indicación para la mirra
CU20100164A7 (es) Sistemas de administración de drogas que contienen estradiol
WO2016014680A3 (en) Oral transmucosal compositions including aromatase inhibitors for low testosterone levels in men
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa
AR089101A1 (es) Formulacion nasal
CO6331424A2 (es) Formulacion farmaceutica de eprosartan
CL2016003271A1 (es) Métodos para tratar infecciones

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20180831